ÇмúÇà»ç
|
|
|
 |
|
|
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2014³â Á¦26Â÷ Workshop °³ÃÖ ¾È³» (Program ¾È³»)
|
ÀÛ¼ºÀÚ
|
°ü¸®ÀÚ
|
Date | 2014³â 10¿ù 16ÀÏ 13:45 | Hits | 5848 |
÷ºÎÆÄÀÏ
|

|
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2014³â Á¦26Â÷ Workshop °³ÃÖ ¾È³»
"Non-clinical studies for Global Drug Development"
¡á Çà»ç°³¿ä
Çà»ç¸í |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2014³â Á¦26Â÷ Workshop |
ÁÖÁ¦ |
Non-clinical studies for Global Drug Development |
ÀϽà |
2014³â 11¿ù 20(¸ñ) ~ 21ÀÏ(±Ý) |
Àå¼Ò |
¿ÀÅ©¹ë¸®¸®Á¶Æ® ½Å±ÔÄÁº¥¼ÇȦ (½ºÅ°¸®Á¶Æ® Ò®) (ÁÖ¼Ò : °¿øµµ ¿øÁֽà ÁöÁ¤¸é ¿ÀÅ©¹ë¸®2±æ 58) |
´Ù¿î·Îµå |
[ °ø¹® ] Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ Á¦25Â÷ Workshop °³ÃÖ ¾È³»
|
¹®ÀÇ |
KSNS »ç¹«±¹ : Tel. 031) 706-2995 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. Áö¼º¹Ì ¼±»ý´Ô |
¡á µî·Ï ¾È³»
- »çÀüµî·Ï ¾È³»
µî·Ï±â°£ |
- 2014³â 10¿ù 21ÀÏ (È) 09½Ã ~ 11¿ù 14ÀÏ (±Ý) 18½Ã |
µî·Ï¹æ¹ý |
- ¿¬±¸È¸ ȨÆäÀÌÁö (www.nonclinical.or.kr) ÇмúÇà»ç > »çÀüµî·Ï ¸Þ´º ÀÌ¿ë
- ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ, »çÀüµî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù. | - µî·Ïºñ
µî·Ïºñ ±¸ºÐ |
»çÀüµî·Ï |
ÇöÀåµî·Ï
|
Á¤È¸¿ø |
100,000 ¿ø |
150,000 ¿ø |
Çлýȸ¿ø |
60,000 ¿ø |
100,000 ¿ø |
- »çÀüµî·Ïºñ : ÀÚ·áÁý, ¼ö·áÁõ, ¼÷¹Ú(5ÀÎ/1½Ç), ½Äºñ Æ÷ÇÔ
- ¼¼±Ý°è»ê¼ ¹ß±Þ(ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇÒ °æ¿ì, ¿Â¶óÀÎ µî·Ï¶§ ¼¼±Ý°è»ê¼ ¹ßÇàÇà¿©ºÎ¸¦ üũÇϰí, »ç¾÷ÀÚµî·ÏÁõ »çº»À» ¹Ýµå½Ã ÷ºÎ
- ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ
| - ¹«ÅëÀåÀÔ±Ý (°èÁÂÀÌü)
ÀԱݰèÁ |
- ¿ì¸®ÀºÇà 1005-101-920320 ¢ß Å¥º£½ºÆ®ÄÁ¼³ÆÃ ºñÀӻ󿬱¸È¸ |
ÀԱݸ¶°¨ |
- ~ 2014³â 11¿ù 14ÀÏ (±Ý) 18½Ã ±îÁö |
- ÀԱݽà ¹Ýµå½Ã "¼Ò¼Ó/¼º¸í" À» ±âÀÔÇϼ¼¿ä.
- ¹«ÅëÀå ÀÔ±Ý(°èÁÂÀÌü)ÀÌü ÈÄ, »ç¹«±¹¿¡¼ ÀÔ±ÝÀ» È®ÀÎÇÏ´Â ½Ã°£ÀÌ 1ÀÏÁ¤µµ ¼Ò¿ä µË´Ï´Ù.
- ½Å¿ëÄ«µå °áÁ¦´Â ºÒ°¡´É ÇÕ´Ï´Ù.
- ±âŸ µî·Ï °ü·Ã ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
TEL. 031-706-2995, E-mail ksns@nonclinical.or.kr, °íÁ¾È
|
¡á ÇÁ·Î±×·¥ ¾È³» (Draft)
DAY 1 : 2014³â 11¿ù 20ÀÏ (¸ñ)
|
Time |
Program |
Speaker |
Chairman |
10:30-11:00 |
Registration |
11:00-11:10 |
Opening Remark |
±èµ¿È¯ ȸÀå |
|
11:10-12:00 |
½Å¾à°³¹ß È帧°ú ±¹³» GLP ÇöȲ |
ÇÑ»ó¼· ±³¼ö
(°Ç¾ç´ë) |
|
12:00-13:00 |
Lunch |
13:00-13:30 |
Booth Exhibition & Coffee Break |
Emerging Technologies in DMPK Study |
13:30-14:10 |
Human mass balance using accelerator mass spectroscopy (AMS) |
ÀÌ¹Î¿ì ¿¬±¸¿ø
(³ì½ÊÀÚ) |
½ÉÇöÁÖ ¹Ú»ç
(µ¿¾ÆST)
|
14:10-14:50 |
Non-CYP drug metabolism in drug development |
ÀÌÇý¼÷ ±³¼ö
(°¡Å縯´ë) |
14:50-15:30 |
Benefits and purposes of modeling and simulation in drug development |
½Å¼Ò¿µ ±³¼ö
(¿ø±¤´ë) |
15:30-16:10 |
PK/PD studies using Bio-imaging |
±è»óÀº ±³¼ö
(¼¿ï´ë) |
16:10-16:40 |
Booth Exhibition & Coffee Break |
Open innovation and licensing strategy |
16:40-17:20 |
Sanofi¡¯s strategy for open innovation and partnering |
Dr. Takato Noumi
(Sanofi)
|
ÀÌ»óÈ£ ¹Ú»ç
(´ë¿õÁ¦¾à)
|
17:20-18:00 |
¼º°øÀû ¶óÀ̼¾½Ì ¾Æ¿ô Àü·« |
¹¬Çö»ó ´ëÇ¥
(¸ÞµðÇÁ·Ð) |
18:00-20:00 |
¼÷¼Ò¹èÁ¤, Annual meeting, Dinner and Recreation activity |
DAY 2 : 2014³â 11¿ù 21ÀÏ (±Ý)
|
Time |
Program |
Speaker |
Chairman |
08:00-09:00 |
Breakfast |
Non-clinical studies in non-rodent species |
09:00-09:40 |
¿µÀå·ù Áúȯ¸ðµ¨ °³¹ß ¹× ¸ðµ¨ Ȱ¿ë »ç·Ê
|
ÀÌ»ó·¡ ¹Ú»ç
(±¹°¡¿µÀå·ù¼¾ÅÍ) |
ÃÖ¿¬½Ä ±³¼ö
(Çѱ¹Æú¸®ÅØ ¹ÙÀÌ¿À´ëÇÐ)
|
09:40-10:20 |
Non-clinical development of SAL200, a novel and potent antibacterial agent |
Àü¼ö¿¬ ¹Ú»ç
(ÀÎÆ®·Ð¹ÙÀÌ¿À) |
10:20-10:40 |
Booth Exhibition & Coffee Break |
10:40-11:20 |
Nonclinical efficacy and toxicology using minipigs |
¹Ú¼Ò¿¬ ¹Ú»ç
(PWG Genetics) |
11:20-12:00 |
´ëü½ÃÇè¹ý °¡À̵å¶óÀÎ ¼Ò°³ |
¾ÈÀÏ¿µ ÁÖ¹«°ü
(½Ä¾àó)
|
12:00-13:00 |
Luncheon (luncheon symposium-KIT ±â¼ú¼³¸íȸ, 12:00-12:30) |
13:00-13:30 |
Booth Exhibition |
Challenges and Opportunities in global drug development |
13:30-14:10 |
Development of Sivextro (Tedizolid): A new Oxazolidinone antibiotics |
ÃÖ¼ºÇÐ ¹Ú»ç
(µ¿¾ÆST)
|
°í¿ì¼® ¹Ú»ç
(ÇÑÈÄɹÌÄ®)
|
14:10-14:50 |
ADC: New site-specific conjugation technology |
¹Úű³ ¹Ú»ç
(·¹°íÄ͹ÙÀÌ¿À»çÀ̾ð½º) |
14:50-15:30 |
Roles of preformulation bridging from discovery to development
|
Á¤¼ºÈÆ ±³¼ö
(µ¿±¹´ë)
|
15:30-15:40 |
Closing Remark |
±èµ¿È¯ ȸÀå |
|
- TBA: To be announced
- »ó±â ÇÁ·Î±×·¥Àº ¿¬ÀÚ ¹× ±âŸ »çÁ¤À¸·Î º¯µ¿ ¼ö ÀÖ½À´Ï´Ù.
¡á ¿ÀÅ©¹ë¸®¸®Á¶Æ® ã¾Æ¿À½Ã´Â ±æ
ÁÖ¼Ò |
°¿øµµ ¿øÁֽà ÁöÁ¤¸é ¿ÀÅ©¹ë¸®2±æ 58
- [³×À̹ö Áöµµ]·Î À§Ä¡ È®ÀÎ ¹× ±³Åë Âü°í :  |
±³ÅëÆí ¾È³» |
¿ÀÅ©¹ë¸®¸®Á¶Æ® ȨÆäÀÌÁö ³» [ã¾Æ¿À½Ã´Â ±æ] ¸Þ´º Âü°í :  |

|
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2014³â Á¦26Â÷ Workshop ÇùÂù ¸ðÁý
(·±Ãµ¼¼¹Ì³ª, ºÎ½º, ±¤°í)
1. ±Í»çÀÇ ¹«±ÃÇÑ ¹ßÀüÀ» ±â¿øÇÏ¿À¸ç, Ç×»ó ÀúÈñ Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡ °ü½ÉÀ» °¡Á®Áֽɿ¡ ±íÀÌ °¨»çµå¸³´Ï´Ù.
2. Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡¼ ÁÖ°üÇÏ´Â Á¦26Â÷ WorkshopÀ» 2014³â 11¿ù 20ÀÏ(¸ñ)~11¿ù 21ÀÏ(±Ý) ¿ÀÅ©¹ë¸®¸®Á¶Æ® ½Å±Ô ÄÁº¥¼ÇȦ¿¡¼ " Non-clinical studies for Global Drug Development "À̶õ ÁÖÁ¦·Î °³ÃÖÇϰíÀÚ ÇÕ´Ï´Ù. ¼º°øÀûÀÎ ÇмúÇà»ç °³ÃÖ¸¦ À§ÇÏ¿© ±Í ±â°üÀÇ ·±Ãµ¼¼¹Ì³ª, ºÎ½º ¹× ±¤°í ÇùÂùÀ» ¿äû µå¸®¿À´Ï Àû±ØÀûÀÎ Âü¿© ºÎŹ µå¸³´Ï´Ù. ¶ÇÇÑ, ±Í»çÀÇ °ü°èÀںе鲲¼µµ ÇмúÇà»ç¿¡ Âü¼®ÇÏ½Ã¾î ±Í»ç¿¡ µµ¿òÀÌ µÉ human networking°ú Çмú±³·ù¸¦ ÇÒ ¼ö ÀÖµµ·Ï ÇùÁ¶ÇÏ¿© ÁÖ½Ã¸é °¨»çÇϰڽÀ´Ï´Ù.
- ´Ù À½ -
Çà»ç¸í |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2014³â Á¦26Â÷ Workshop |
ÁÖÁ¦ |
Non-clinical studies for Global Drug Development |
ÀϽà |
2014³â 11¿ù 20(¸ñ) ~ 21ÀÏ(±Ý) |
Àå¼Ò |
¿ÀÅ©¹ë¸®¸®Á¶Æ® ½Å±Ô ÄÁº¥¼ÇȦ (½ºÅ°¸®Á¶Æ® Ò®) (ÁÖ¼Ò : °¿øµµ ¿øÁֽà ÁöÁ¤¸é ¿ÀÅ©¹ë¸®2±æ 58) |
ÇùÂù³»¿ë |
1) ·±Ãµ¼¼¹Ì³ª(ºÎ½º/±¤°í ¹× µµ½Ã¶ôºñ¿ë Æ÷ÇÔ): \5,000,000 (VATº°µµ)
* Á¡½É½Ã°£(12:00~13:00) / ½Ä»çÀοøÀº »çÀüµî·Ï ¸¶°¨ ÈÄ Å뺸 (2013³â ¾à 140¸í)
* 20ÀÏ(¸ñ) ¹× 21ÀÏ(±Ý) 2°³ÀÇ ·±Ãµ¼¼¹Ì³ª ¸ðÁý
2) ºÎ½º(±¤°í Æ÷ÇÔ): \2,000,000 (VATº°µµ)
* ÇùÂù¾÷ü °ü°èÀÚ 2¸í¿¡ ÇÑÇÏ¿© Çмú´ëȸ Âü°¡ºñ ¹«·á
* ¼Ò¿¬È¸Àå¿¡ 2X2 ¹ÌÅÍ Å©±âÀÇ ºÎ½º ¼³Ä¡ °¡´É /ºÎ½º ´ç Å×À̺í 1°³ ¹× ÀÇÀÚ 2°³ Á¦°ø
* ºÎ½º¼³Ä¡¿Í °ü·Ã À¯ÀÇ»çÇ× ¹× Áغñ»çÇ×Àº ÃßÈÄ °øÁö
3) ±¤°í(ÀÚ·áÁý): \1,000,000 (VATº°µµ) |
¸¶°¨ÀÏÀÚ |
2014³â 11¿ù 07ÀÏ (±Ý)
* ·±Ãµ¼¼¹Ì³ª ¹× ºÎ½ºÀÇ °æ¿ì, ¼±Âø¼ø ¸¶°¨ (ºÎ½º¼³Ä¡ À§Ä¡´Â ¿öÅ©¼¥ ´çÀÏ Ãß÷/ÁöÁ¤) |
ÀԱݰèÁ |
¿ì¸®ÀºÇà 1005-101-920320 ¢ßÅ¥º£½ºÆ®ÄÁ¼³ÆÃºñÀӻ󿬱¸È¸ |
°ü·Ã°ø¹® |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2014³â Á¦26Â÷ Workshop ÇùÂù ¸ðÁý (·±Ãµ¼¼¹Ì³ª, ºÎ½º, ±¤°í) |
¹®ÀÇ |
ÇùÂù°ú °ü·ÃÇØ ±Ã±ÝÇϽŠ»çÇ×Àº KSNS »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù
KSNS »ç¹«±¹ : Tel. 031) 706-2995 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. °íÁ¾È |
|
|
|
 |
|
|